EyePoint, Inc. (EYPT) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · General / Diversified · as of Jun 27, 2026
EyePoint, Inc. (EYPT)
A forensic read on EyePoint, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-3.6
Altman Z-score
Clean
Earnings quality
2
Forensic signals
-110.5%
ROE
$1.1B
Market cap
EyePoint, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -3.6, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-85%Return on invested capital.Return on invested capital is -85% and rising from -130% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
89% of revStock-based comp load.Stock-based compensation ran 89% of revenue in FY2025 — about $380.51 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-739.4%
Debt / Equity0.10x
Free Cash Flow$-243.4M
Latest Revenue$31.4M
Return on Equity-75.8%
Revenue Growth YoY-27.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on EyePoint, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about EYPT's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown